Subtype
Uterine Corpus Neoplasm
CI-CAN-00007035Explore in graph →
Non-malignant451 active trials4 approved drugs28 evidence items
- NCIt
- C6300
Loading cancer entity…
Subtype
CI-CAN-00007035Explore in graph →
Clinical trials
1,714 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00378911 | Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00416455 | Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer | completed | Phase 1 / Phase 2 | 384 | National Cancer Institute (NCI)NIH | 4 |
| Jul 23, 2019 |
| clinicaltrials |
| NCT00462826 | VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00723255 | Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00729586 | Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer | completed | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01011933 | Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01637961 | Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01523678 | Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers | completed | Phase 2 | 108 | Belgian Gynaecological Oncology GroupOTHER | 1 | Jul 10, 2019 | clinicaltrials |
| NCT02323646 | Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids | completed | Phase 2 | 42 | Repros Therapeutics Inc.INDUSTRY | 1 | Jun 25, 2019 | clinicaltrials |
| NCT00958334 | Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003 | completed | Phase 2 | 65 | Repros Therapeutics Inc.INDUSTRY | 1 | Jun 18, 2019 | clinicaltrials |
| NCT01289041 | BKM120 as Second-line Therapy for Advanced Endometrial Cancer | completed | Phase 2 | 70 | Novartis PharmaceuticalsINDUSTRY | 13 | May 30, 2019 | clinicaltrials |
| NCT01717391 | [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers | completed | Phase 2 | 36 | John M. BuattiOTHER | 1 | Mar 26, 2019 | clinicaltrials |
| NCT01267253 | Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Mar 20, 2019 | clinicaltrials |
| NCT00331760 | Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery | completed | Phase 2 | 106 | Radiation Therapy Oncology GroupNETWORK | 2 | Feb 26, 2019 | clinicaltrials |
| NCT00910091 | The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer | completed | Phase 2 | 73 | IpsenINDUSTRY | 12 | Jan 30, 2019 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT00114218 | Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 28 | Gynecologic Oncology GroupNETWORK | 1 | Jan 8, 2019 | clinicaltrials |
| NCT00309959 | ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 37 | Gynecologic Oncology GroupNETWORK | 1 | Jan 8, 2019 | clinicaltrials |
| NCT02091050 | 2D vs 3D Planning for High-Dose Rate (HDR) Gynecological Brachytherapy | completed | Phase 2 | 60 | AC Camargo Cancer CenterOTHER | 1 | Aug 31, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT01553539 | Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery | completed | Phase 2 | 20 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT00659360 | AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 2 | Jun 29, 2018 | clinicaltrials |
| NCT01764802 | Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer | completed | Phase 2 | 100 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT00483327 | Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate | completed | Phase 2 | 31 | NYU Langone HealthOTHER | 1 | Apr 4, 2018 | clinicaltrials |
| NCT00369122 | Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 2 | Mar 20, 2018 | clinicaltrials |
| NCT01005329 | Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 3 | Mar 15, 2018 | clinicaltrials |
| NCT01642082 | Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 28 | Gynecologic Oncology GroupNETWORK | 1 | Mar 13, 2018 | clinicaltrials |
| NCT01210222 | Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer | completed | Phase 2 | 35 | Gynecologic Oncology GroupNETWORK | 1 | Feb 23, 2018 | clinicaltrials |
| NCT00820898 | Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 24 | Gynecologic Oncology GroupNETWORK | 1 | Dec 29, 2017 | clinicaltrials |
| NCT00258362 | Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer | completed | Phase 2 | 41 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00381888 | Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer | completed | Phase 2 | 44 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00610740 | CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer | completed | Phase 2 | 18 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00888173 | Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 45 | Gynecologic Oncology GroupNETWORK | 1 | Dec 6, 2017 | clinicaltrials |
| NCT01225887 | Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 37 | Gynecologic Oncology GroupNETWORK | 1 | Oct 9, 2017 | clinicaltrials |
| NCT00039442 | Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 21 | Gynecologic Oncology GroupNETWORK | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00332033 | Development of a Non-Invasive Treatment for Uterine Leiomyoma (Fibroids) | completed | Phase 2 | 32 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00879359 | Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer | completed | Phase 2 | 15 | The Cleveland ClinicOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT00545792 | Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers | completed | Phase 2 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT00031629 | Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus | completed | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Dec 8, 2016 | clinicaltrials |
| NCT02150213 | Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 5, 2016 | clinicaltrials |
| NCT00171808 | Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer(deFEND) | completed | Phase 2 | 26 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 18, 2016 | clinicaltrials |
| NCT02017353 | Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma | completed | Phase 2 | 7 | University Hospital, GasthuisbergOTHER | 1 | Oct 25, 2016 | clinicaltrials |
| NCT01455493 | A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma | completed | Phase 2 | 56 | Genentech, Inc.INDUSTRY | 1 | Aug 11, 2016 | clinicaltrials |
| NCT01013324 | Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma | completed | Phase 2 | 67 | SanofiINDUSTRY | 2 | Jun 3, 2016 | clinicaltrials |
| NCT00064025 | Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus | completed | Phase 2 | 75 | Gynecologic Oncology GroupNETWORK | 1 | Apr 11, 2016 | clinicaltrials |
| NCT00003334 | Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract | completed | Phase 2 | — | NYU Langone HealthOTHER | 1 | Mar 11, 2016 | clinicaltrials |
| NCT01460979 | Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma | completed | Phase 2 | 47 | AGO Study GroupOTHER | 1 | Feb 29, 2016 | clinicaltrials |
| NCT00474994 | Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas | completed | Phase 2 | 53 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 20, 2016 | clinicaltrials |
| NCT00390234 | Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma | completed | Phase 2 | 63 | National Cancer Institute (NCI)NIH | 2 | Dec 7, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Jul 23, 2019source: clinicaltrials